The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Retigabine [RTG (international nonproprietary name); ezogabine (EZG; U.S. adopted name)] is a first‐in‐class antiepileptic drug (AED) that reduces neuronal excitability by enhancing the activity of KCNQ (K v 7) potassium (K+) channels. RTG/EZG has recently been approved by the European Medicines Agency and the U.S. Food and Drug Administration as adjunctive therapy in adults with partial‐onset seizures. In this review we discuss the activity that RTG/EZG has demonstrated across a broad spectrum of in vitro/in vivo animal models of seizures, including generalized tonic–clonic, primary generalized (absence), and partial seizures, in addition to the compound’s ability to resist and block the occurrence of seizures induced by a range of stimuli across different regions of the brain. The potency of RTG/EZG in models refractory to several conventional AEDs and the work done to assess antiepileptogenesis and neuroprotection are discussed. Studies that have evaluated the central nervous system side effects of RTG/EZG in animals are reviewed in order to compare these effects with adverse events observed in patients with epilepsy. Based on its demonstrated effect in a number of animal epilepsy models, the synergistic and additive activity of RTG/EZG with other AEDs supports its potential use in therapeutic combinations for different seizure types. The distinct mechanism of action of RTG/EZG from those of currently available AEDs, along with its broad preclinical activity, underscores the key role of KCNQ (K v 7) K+ channels in neuronal excitability, and further supports the potential efficacy of this unique molecule in the treatment of epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
Singh, N. A., Charlier, C., Stauffer, D., DuPont, B. R., Leach, R. J., Melis, R., Ronen, G. M., Bjerre, I., Quattlebaum, T., Murphy, J. V., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-25 · Cited by 1,199
A Potassium Channel Mutation in Neonatal Human Epilepsy
Biervert, C., Schroeder, B. C., Kubisch, C., Berkovic, S. F., Propping, P., Jentsch, T. J., & Steinlein, O. K. (1998) · Science · doi:10.1126/science.279.5349.403 · Cited by 1,073 · cited 1×
“3 and 8q24, and the associated genes were subsequently identified as KCNQ2 and KCNQ3, respectively (Biervert et al., 1998; Singh et al., 1998; Charlier et al., 1998).”
BackgroundLarge, C. H., Kalinichev, M., Lucas, A., Carignani, C., Bradford, A., Garbati, N., Sartori, I., Austin, N. E., Ruffo, A., Jones, D. N. C., et al. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.02.018 · Cited by 45 · cited 14×
“Several older anticonvulsants, such as PHT, PB, and VPA have been shown to reduce seizure severity at therapeutically relevant doses (Walton & Treiman, 1988, 1992), whereas LTG was ineffective (Walton et al., 1996).”
BackgroundInfluentialSelf-citation
Cited by
Gunthorpe, M. J., Large, C. H., & Sankar, R. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03365.x · Cited by 319
Self-citationBloms-Funke, P., Bankstahl, M., Bankstahl, J., Kneip, C., Schröder, W., & Löscher, W. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108884 · Cited by 19
Grupe, M., Bentzen, B. H., Benned-Jensen, T., Nielsen, V., Frederiksen, K., Jensen, H. S., Jacobsen, A.-M., Skibsbye, L., Sams, A. G., Grunnet, M., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173440 · Cited by 19
Zahra, A., Liu, R., Wang, J., & Wu, J. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06955-x · Cited by 9
Metadata
- Authors
- Large, C. H., Sokal, D. M., Nehlig, A., Gunthorpe, M. J., Sankar, R., Crean, C. S., VanLandingham, K. E., & White, H. S.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-01-05
- Volume
- 53
- Issue
- 3
- Pages
- 425-436
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1596694562
- Cited by
- 73
- References
- 3
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. https://app.cochat.ai/papers/10.1111/j.1528-1167.2011.03364.x
- The paper
- Large, C. H., Sokal, D. M., Nehlig, A., Gunthorpe, M. J., Sankar, R., Crean, C. S., VanLandingham, K. E., & White, H. S. (2012). The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. Epilepsia. https://doi.org/10.1111/j.1528-1167.2011.03364.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.